Comparing Ga-68-DOTATATE and Ga-68-DOTATOC for Meningioma
This study is comparing two imaging agents, Ga-68-DOTATATE and Ga-68-DOTATOC, used in PET scans (a type of imaging test) for patients with meningioma (a type of brain tumor). The goal is to see which agent provides clearer images of the tumor compared to surrounding brain tissue. Researchers want to find out if Ga-68-DOTATOC is as good as Ga-68-DOTATATE, potentially leading to a more cost-effective imaging method. You may be able to join if you are an adult with suspected meningioma, are planning to have surgery, and have no reasons preventing you from receiving these imaging agents. The study aims to measure how well each agent highlights the tumor visually and quantitatively. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 6 participants. It directly compares two different imaging agents.
- What's involved
- You would undergo two PET scans using the different imaging agents. You must be able to lie still on the scanner table for the required time.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes will be measured over 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jana Ivanidze, MD/Ph.D · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Qualitatively measure the visual appearance of target lesion to cranial blood pool using the maximum SUV ratio to compare results from Ga-68-DOTATATE and -DOTATOC PET.Over 12 months
Compare visual appearance qualitatively using the maximum SUV ratio of target lesion to cranial blood pool (i.e. superior sagittal sinus reference region) of DOTATATE and DOTATOC PET scans in patients with meningioma. Based on our pilot clinical case series, the following reference regions will be evaluated: 1. Suspected meningioma; 2. Pituitary gland; 3. Superior sagittal sinus; 4. Brain parenchyma. Dynamic PET will be acquired and data will be analyzed including comparison of tissue-activity curves and Patlak analysis, as established by the PI in a pilot cohort. Extent of meningioma based on Ga-68-DOTATATE- and DOTATOC PET/CT will be compared to extent of disease as determined by MRI.
- Quantitatively measure the visual appearance of target lesion to cranial blood pool using the maximum SUV ratio to compare results from Ga-68-DOTATATE and -DOTATOC PET.Over 12 months
Compare visual appearance quantitatively using the maximum SUV ratio of target lesion to cranial blood pool (i.e. superior sagittal sinus reference region) of DOTATATE and DOTATOC PET scans in patients with meningioma. Qualitative analysis will include evaluation by board certified radiologists with expertise in nuclear medicine/ molecular imaging who will be blinded to the radiotracer injected. Quantitative analysis will include extraction of the ratio of lesion's SUVmax values/reference regions.